Gastric cancer immunotherapy
- Conditions
- gastric cancer.Malignant neoplasm of stomach
- Registration Number
- IRCT20170208032451N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 5
Patients with gastric adenocarcinoma whose histologically advanced malignancy (spread of cancer cells to lymph nodes and tumor metastasis) has been confirmed and they have filled out the informed consent form
The patient must be over 18 years old at the time of diagnosis.
Natural laboratory parameters, including these tests: Protein C& S, D-Dimer, VWF, CPK,LDH, TI, ALP, Lipase, Amylase, GGT, OB,CBC diff, Hgb electrophoresis, Serum Iron, Transferrin saturation, TIBC, CH50 (total complement), ESR, CRP, ACE, ANA, Anti CCP, RF, Auto antibodies, UA, Uric acid, Cr, Urea, SGPT, SGOT, Bilirubin, Albumin, Lipid profile, ACTH, Cortisol, FBS, HbA1c, OGT , ACTH, Cortisol, FBS, HbA1c, OGTT, Insulin, PTH, GH, Calcitonin, TFT, Testosterone, LH, FSH, Estrogen, Progestrone, PRL.
To start immunotherapy, at least 4 weeks must have passed since the last course of chemotherapy or radiotherapy, and all the side effects of chemotherapy must be eliminated.
Functional condition according to Karnowski criteria should be more than 60%
Expected survival rate more than 6 months
brain metastasis
autoimmune diseases
Abnormal function of heart, liver, kidney, brain and other important organs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Side effect. Timepoint: 7 days. Method of measurement: clinical measurement.
- Secondary Outcome Measures
Name Time Method Clinical and immune response. Timepoint: one year. Method of measurement: Flow cytometry - ELISA - Overall survival rate - Tumor-free survival rate.